# Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer

> **NCT03747484** · PHASE1,PHASE2 · TERMINATED · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 7 (actual)

## Conditions studied

- Other Skin

## Interventions

- **BIOLOGICAL:** Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR
- **DRUG:** Avelumab
- **BIOLOGICAL:** Pembrolizumab
- **BIOLOGICAL:** Interferon Gamma-1b

## Key facts

- **NCT ID:** NCT03747484
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-07-03
- **Primary completion:** 2024-01-09
- **Final completion:** 2024-01-09
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Terminated due to insufficient funding
- **Last updated:** 2025-03-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03747484

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03747484, "Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03747484. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*